Sana Biotechnology Inc. (SANA)
| Bid | 1.7 |
| Market Cap | 377.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -266.76M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 1.76 |
| Volume | 1,846,681 |
| Avg. Volume (20D) | 4,235,516 |
| Open | 1.81 |
| Previous Close | 1.81 |
| Day's Range | 1.66 - 1.92 |
| 52-Week Range | 1.26 - 10.50 |
| Beta | 1.78 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...
Analyst Forecast
According to 6 analyst ratings, the average rating for SANA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 432.51% from the latest price.
Stock Forecasts
23 hours ago · accessnewswire.com
May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANANEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securi...
